PE20171136A1 - Metodo para la cuantificacion absoluta de peptidos cancerosos restringidos a hla que son procesados de forma natural - Google Patents
Metodo para la cuantificacion absoluta de peptidos cancerosos restringidos a hla que son procesados de forma naturalInfo
- Publication number
- PE20171136A1 PE20171136A1 PE2017000941A PE2017000941A PE20171136A1 PE 20171136 A1 PE20171136 A1 PE 20171136A1 PE 2017000941 A PE2017000941 A PE 2017000941A PE 2017000941 A PE2017000941 A PE 2017000941A PE 20171136 A1 PE20171136 A1 PE 20171136A1
- Authority
- PE
- Peru
- Prior art keywords
- mhc
- peptide ligand
- peptide
- absolute quantification
- hla
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 11
- 238000000034 method Methods 0.000 title abstract 4
- 238000011002 quantification Methods 0.000 title abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 abstract 7
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 abstract 7
- 239000003446 ligand Substances 0.000 abstract 6
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 239000012472 biological sample Substances 0.000 abstract 1
- 238000011293 immunotherapeutic strategy Methods 0.000 abstract 1
- 238000004949 mass spectrometry Methods 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6848—Methods of protein analysis involving mass spectrometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56977—HLA or MHC typing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in epitope analysis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70539—MHC-molecules, e.g. HLA-molecules
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2458/00—Labels used in chemical analysis of biological material
- G01N2458/15—Non-radioactive isotope labels, e.g. for detection by mass spectrometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2496/00—Reference solutions for assays of biological material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2560/00—Chemical aspects of mass spectrometric analysis of biological material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Zoology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Abstract
Se refiere a un metodo para la cuantificacion absoluta de un ligando peptidico del complejo mayor de histocompatibilidad (MHC) radicado sobre una celula, que comprende: a) preparacion de celulas que presentan el ligando peptidico de MHC a partir de una muestra biologica; b) determinacion del numero de celulas en la preparacion resultante de la etapa a); c) adicionar una cantidad conocida del ligando peptidico-MHC y/o complejo de ligando peptidico-MHC de la etapa a) que se pretende cuantificar (1er enriquecimiento); d) aislar un ligando peptidico del MHC resultante de la preparacion de la etapa c) con el fin de obtener un eluato del peptido; e) adicionar una cantidad conocida del ligando peptidico del MHC que se pretende cuantificar al citado eluato (2do enriquecimiento); f) ejecutar un analisis por espectrometria de masas con un ligando peptidico de MHC; y g) cuantificacion del citado ligando peptidico del MHC basada en la comparacion de las las senales obtenidas en la etapa f). Dicho metodo es util en la inmunovigilancia definida con criterios moleculares y en los procesos de identificacion de nuevos antigenos peptidicos para estrategias inmunoterapeuticas
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462097994P | 2014-12-30 | 2014-12-30 | |
| GBGB1423361.3A GB201423361D0 (en) | 2014-12-30 | 2014-12-30 | Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20171136A1 true PE20171136A1 (es) | 2017-08-09 |
Family
ID=52471641
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2017000941A PE20171136A1 (es) | 2014-12-30 | 2015-12-15 | Metodo para la cuantificacion absoluta de peptidos cancerosos restringidos a hla que son procesados de forma natural |
Country Status (35)
| Country | Link |
|---|---|
| US (3) | US10545154B2 (es) |
| EP (1) | EP3241026B1 (es) |
| JP (1) | JP6735741B2 (es) |
| KR (1) | KR102336968B1 (es) |
| CN (1) | CN107003322B (es) |
| AU (1) | AU2015373584B2 (es) |
| BR (1) | BR112017008212B1 (es) |
| CA (1) | CA2972306C (es) |
| CL (1) | CL2017001071A1 (es) |
| CO (1) | CO2017004543A2 (es) |
| CR (1) | CR20170297A (es) |
| CY (1) | CY1124223T1 (es) |
| DK (1) | DK3241026T3 (es) |
| EA (1) | EA036328B1 (es) |
| ES (1) | ES2871035T3 (es) |
| GB (1) | GB201423361D0 (es) |
| HR (1) | HRP20210811T1 (es) |
| HU (1) | HUE054455T2 (es) |
| IL (1) | IL250982B (es) |
| LT (1) | LT3241026T (es) |
| MA (2) | MA40137B1 (es) |
| MD (1) | MD3241026T2 (es) |
| MX (1) | MX383806B (es) |
| MY (1) | MY190199A (es) |
| PE (1) | PE20171136A1 (es) |
| PH (1) | PH12017500483A1 (es) |
| PL (1) | PL3241026T3 (es) |
| PT (1) | PT3241026T (es) |
| RS (1) | RS61914B1 (es) |
| SG (2) | SG11201703841VA (es) |
| SI (1) | SI3241026T1 (es) |
| TW (1) | TWI632370B (es) |
| UA (1) | UA122774C2 (es) |
| WO (1) | WO2016107740A1 (es) |
| ZA (1) | ZA201701646B (es) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201423361D0 (en) * | 2014-12-30 | 2015-02-11 | Immatics Biotechnologies Gmbh | Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides |
| CR20210232A (es) | 2015-03-17 | 2022-06-24 | Immatics Biotechnologies Gmbh | NUEVOS PÉPTIDOS Y NUEVA COMBINACIÓN DE PÉPTIDOS PARA EL USO EN LA INMUNOTERAPIA CONTRA EL CÁNCER DE PÁNCREAS Y OTROS TIPOS DE CÁNCER (Divisional 2017-0419) |
| GB201513921D0 (en) | 2015-08-05 | 2015-09-23 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers |
| PH12022551111A1 (en) | 2015-10-05 | 2023-08-23 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers |
| GB201604458D0 (en) | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against cancers |
| EP4317432A3 (en) | 2016-12-08 | 2024-04-17 | Immatics Biotechnologies GmbH | T cell receptors with improved pairing |
| DE102016123893A1 (de) | 2016-12-08 | 2018-06-14 | Immatics Biotechnologies Gmbh | T-Zellrezeptoren mit verbesserter Bindung |
| US20190016802A1 (en) | 2017-07-14 | 2019-01-17 | Immatics Biotechnologies Gmbh | Dual specificity polypeptide molecule |
| DE102017127984B4 (de) | 2017-11-27 | 2019-12-05 | Immatics US, Inc. | Verfahren für die Vermehrung und Aktivierung von γδ-T-Zellen |
| KR20200119840A (ko) * | 2018-02-09 | 2020-10-20 | 이매틱스 유에스 인코포레이티드 | T 세포의 제조 방법 |
| DE102018107224A1 (de) | 2018-02-21 | 2019-08-22 | Immatics Biotechnologies Gmbh | Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten |
| DE102018108612A1 (de) | 2018-03-21 | 2019-09-26 | Immatics US, Inc. | Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen |
| KR102731127B1 (ko) * | 2018-09-05 | 2024-11-18 | 에스케이하이닉스 주식회사 | 메모리 컨트롤러 및 이를 포함하는 메모리 시스템 |
| TW202039535A (zh) | 2018-12-18 | 2020-11-01 | 德商英麥提克生物技術股份有限公司 | B*08限制肽和肽組合物抗癌免疫治療和相關方法 |
| US20200297768A1 (en) | 2019-03-19 | 2020-09-24 | Immatics US, Inc. | Cd28 t cell cultures, compositions, and methods of using thereof |
| KR20220029584A (ko) | 2019-05-27 | 2022-03-08 | 이매틱스 유에스 인코포레이티드 | 바이러스 벡터 및 입양 세포 요법에서 그 사용 |
| AU2020286756A1 (en) | 2019-06-06 | 2022-01-27 | Immatics Biotechnologies Gmbh | Sorting with counter selection using sequence similar peptides |
| DE102019121007A1 (de) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Antigenbindende Proteine, die spezifisch an MAGE-A binden |
| US20210032370A1 (en) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Recruiting agent further binding an mhc molecule |
| JP2022543687A (ja) | 2019-08-09 | 2022-10-13 | イマティクス ユーエス，アイエヌシー． | ペプチド質量分析断片化を予測するための方法 |
| US12480958B2 (en) * | 2019-08-13 | 2025-11-25 | Immatics Biotechnologies Gmbh | Method for the characterization of peptide:MHC binding polypeptides |
| JP2023515131A (ja) | 2020-02-24 | 2023-04-12 | イマティクス ユーエス，アイエヌシー． | がんおよび関連する悪性腫瘍の治療のためにｔ細胞を増殖させる方法 |
| DE102020111571A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| DE102020106710A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| WO2021236638A1 (en) | 2020-05-19 | 2021-11-25 | Amgen Inc. | Mageb2 binding constructs |
| WO2022040631A1 (en) | 2020-08-21 | 2022-02-24 | Immatics US, Inc. | Methods for isolating cd8+ selected t cells |
| DE102020125457A1 (de) | 2020-09-29 | 2022-03-31 | Immatics Biotechnologies Gmbh | Amidierte Peptide und ihre deamidierten Gegenstücke, die durch HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten |
| CR20230295A (es) | 2020-12-31 | 2023-07-27 | Immatics Us Inc | Polipéptidos cd8, composiciones y métodos de uso de estos |
| KR20240004937A (ko) | 2021-05-05 | 2024-01-11 | 이매틱스 바이오테크놀로지스 게엠베하 | Bma031 항원 결합 폴리펩타이드 |
| WO2022233956A1 (en) | 2021-05-05 | 2022-11-10 | Immatics Biotechnologies Gmbh | Antigen binding proteins specifically binding prame |
| EP4113120A1 (en) | 2021-06-28 | 2023-01-04 | Immatics Biotechnologies GmbH | Method of characterizing the binding characteristics between a peptide of interest and mhc molecules |
| US20230024554A1 (en) | 2021-06-28 | 2023-01-26 | Immatics Biotechnologies Gmbh | Method of characterizing the binding characteristics between a peptide of interest and mhc molecules |
| JP2024529467A (ja) | 2021-07-27 | 2024-08-06 | イマティクス バイオテクノロジーズ ゲーエムベーハー | Ｃｔ４５に特異的に結合する抗原結合タンパク質 |
| EP4392441A1 (en) | 2021-08-24 | 2024-07-03 | Immatics US, Inc. | Selection of immune cells using peptide mhc complexes generated by conditional ligand exchange |
| US20230089392A1 (en) | 2021-09-20 | 2023-03-23 | Immatics US, Inc. | Monocyte depletion of t cells populations for t-cell therapy |
| CN118541392A (zh) | 2021-09-28 | 2024-08-23 | 准星生物医药有限公司 | 多种形式的分子复合物 |
| US20230190807A1 (en) | 2021-10-06 | 2023-06-22 | Immatics Biotechnologies Gmbh | Tcr compounds, compositions, and methods of treating |
| WO2023081925A1 (en) | 2021-11-08 | 2023-05-11 | Immatics Biotechnologies Gmbh | Adoptive cell therapy combination treatment and compositions thereof |
| WO2023212655A1 (en) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof |
| US20230348561A1 (en) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | Dominant negative tgfbeta receptor polypeptides, cd8 polypeptides, cells, compositions, and methods of using thereof |
| KR20250018168A (ko) | 2022-04-28 | 2025-02-04 | 이매틱스 유에스 인코포레이티드 | 막-결합된 il-15, cd8 폴리펩티드, 세포, 조성물, 및 이의 사용 방법 |
| EP4519418A1 (en) | 2022-05-05 | 2025-03-12 | Immatics US, Inc. | Methods for improving t cell efficacy |
| EP4740019A1 (en) | 2023-07-05 | 2026-05-13 | Immatics Biotechnologies GmbH | A method of identifying mhc-binding proteins and interacting peptides in a sample |
| EP4750807A1 (en) | 2023-07-27 | 2026-06-03 | Immatics Biotechnologies GmbH | Novel t cell receptors targeting melanoma-associated antigen (mage) b2 and immune therapy using the same |
| EP4750806A1 (en) | 2023-07-27 | 2026-06-03 | Immatics Biotechnologies GmbH | Antigen binding proteins against mageb2 |
| EP4761754A2 (en) | 2023-08-18 | 2026-06-24 | Immatics Biotechnologies GmbH | Peptides displayed by mhc for use in immunotherapy against different types of cancer |
| US20250134931A1 (en) | 2023-11-01 | 2025-05-01 | Immatics US, Inc. | Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof |
| WO2025125535A1 (en) | 2023-12-13 | 2025-06-19 | Immatics Biotechnologies Gmbh | Differential population-scale immunopeptidomics |
| WO2025125536A1 (en) | 2023-12-13 | 2025-06-19 | Immatics Biotechnologies Gmbh | Absolute copy number prediction of mhc-presented peptides by relative quantitative measurement |
| WO2025233432A1 (en) | 2024-05-07 | 2025-11-13 | Immatics Biotechnologies Gmbh | Use and dosage of an antigen-binding protein comprising a tcr specific for an hla-a*02 restricted peptide |
| WO2025233431A1 (en) | 2024-05-07 | 2025-11-13 | Immatics Biotechnologies Gmbh | Heteromeric proteins comprising three heteromerization improving substitution, production, combinations and applications thereof |
| WO2026008886A1 (en) | 2024-07-05 | 2026-01-08 | Immatics Biotechnologies Gmbh | Means and methods for the quantification of target expression |
| WO2026033136A1 (en) | 2024-08-09 | 2026-02-12 | Immatics Biotechnologies Gmbh | Advanced treatment modalities for anti-prame tcr-engineered immune cells |
| WO2026096743A1 (en) | 2024-10-30 | 2026-05-07 | Immatics US, Inc. | Methods for gamma delta t cells manufacturing |
| WO2026104504A1 (en) | 2024-11-15 | 2026-05-21 | Immatics Biotechnologies Gmbh | Dosing of prame-specific tcer |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1425586B1 (en) | 2001-09-14 | 2007-11-21 | Electrophoretics Limited | Mass labels |
| US20050221350A1 (en) * | 2002-05-29 | 2005-10-06 | Toni Weinschenk | Method for identifying immunoreactive peptides |
| DE10225139A1 (de) | 2002-05-29 | 2004-02-26 | Immatics Biotechnologies Gmbh | Verfahren zur Identifizierung von immunreaktiven Peptiden |
| US6644103B1 (en) | 2002-10-24 | 2003-11-11 | Simmonds Precision Products, Inc. | Method and apparatus for detecting a dry/wet state of a thermistor bead |
| EP1566639A4 (en) | 2002-11-08 | 2006-10-11 | Hiroshi Takahashi | METHOD FOR EXAMINING CANCER CELLS AND REAGENT THEREOF |
| JP2007519910A (ja) | 2004-01-28 | 2007-07-19 | イマティクス バイオテクノロジーズ ゲーエムベーハー | 腫瘍関連ペプチドの同定および定量方法 |
| JP2008043332A (ja) * | 2006-08-17 | 2008-02-28 | Panomics Inc | 組織スライドからの核酸定量 |
| ES2536465T3 (es) * | 2008-10-01 | 2015-05-25 | Immatics Biotechnologies Gmbh | Composición de péptidos tumor-asociados y relacionados con la vacuna contra el cáncer para el tratamiento de glioblastoma (GBM) y otros cánceres |
| GB201004551D0 (en) * | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer |
| GB201006360D0 (en) * | 2010-04-16 | 2010-06-02 | Immatics Biotechnologies Gmbh | Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development |
| US20140051092A1 (en) | 2011-04-15 | 2014-02-20 | Micromass Uk Limited | Method And Apparatus For The Analysis Of Biological Samples |
| WO2012178030A2 (en) | 2011-06-24 | 2012-12-27 | Applied Isotope Technologies, Inc. | Accurate measurement of glutathione for disease diagnosis and drug metabolite screening |
| US10077171B2 (en) * | 2012-10-17 | 2018-09-18 | Grant C. Chustz | Safety barrier for vehicles and cranes |
| GB201423361D0 (en) * | 2014-12-30 | 2015-02-11 | Immatics Biotechnologies Gmbh | Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides |
| DE102016115246C5 (de) * | 2016-08-17 | 2018-12-20 | Immatics Biotechnologies Gmbh | Neue t-zellrezeptoren und deren verwendung in immuntherapie |
| WO2019086665A1 (en) * | 2017-11-06 | 2019-05-09 | Immatics Biotechnologies Gmbh | Novel engineered t cell receptors and immune therapy using the same |
-
2014
- 2014-12-30 GB GBGB1423361.3A patent/GB201423361D0/en not_active Ceased
-
2015
- 2015-12-15 MD MDE20170252T patent/MD3241026T2/ro unknown
- 2015-12-15 KR KR1020177017911A patent/KR102336968B1/ko active Active
- 2015-12-15 HR HRP20210811TT patent/HRP20210811T1/hr unknown
- 2015-12-15 PE PE2017000941A patent/PE20171136A1/es unknown
- 2015-12-15 WO PCT/EP2015/079873 patent/WO2016107740A1/en not_active Ceased
- 2015-12-15 JP JP2017521534A patent/JP6735741B2/ja active Active
- 2015-12-15 UA UAA201701977A patent/UA122774C2/uk unknown
- 2015-12-15 EA EA201791148A patent/EA036328B1/ru unknown
- 2015-12-15 TW TW104142137A patent/TWI632370B/zh not_active IP Right Cessation
- 2015-12-15 ES ES15822924T patent/ES2871035T3/es active Active
- 2015-12-15 PT PT158229245T patent/PT3241026T/pt unknown
- 2015-12-15 MA MA40137A patent/MA40137B1/fr unknown
- 2015-12-15 LT LTEP15822924.5T patent/LT3241026T/lt unknown
- 2015-12-15 SG SG11201703841VA patent/SG11201703841VA/en unknown
- 2015-12-15 EP EP15822924.5A patent/EP3241026B1/en active Active
- 2015-12-15 MX MX2017008722A patent/MX383806B/es unknown
- 2015-12-15 MA MA41287A patent/MA41287B1/fr unknown
- 2015-12-15 RS RS20210672A patent/RS61914B1/sr unknown
- 2015-12-15 HU HUE15822924A patent/HUE054455T2/hu unknown
- 2015-12-15 BR BR112017008212-8A patent/BR112017008212B1/pt active IP Right Grant
- 2015-12-15 SG SG10201913988XA patent/SG10201913988XA/en unknown
- 2015-12-15 AU AU2015373584A patent/AU2015373584B2/en not_active Ceased
- 2015-12-15 US US14/969,423 patent/US10545154B2/en active Active
- 2015-12-15 DK DK15822924.5T patent/DK3241026T3/da active
- 2015-12-15 SI SI201531612T patent/SI3241026T1/sl unknown
- 2015-12-15 CR CR20170297A patent/CR20170297A/es unknown
- 2015-12-15 PL PL15822924T patent/PL3241026T3/pl unknown
- 2015-12-15 CN CN201580063711.6A patent/CN107003322B/zh not_active Expired - Fee Related
- 2015-12-15 CA CA2972306A patent/CA2972306C/en active Active
- 2015-12-15 MY MYPI2017700825A patent/MY190199A/en unknown
-
2017
- 2017-03-07 IL IL250982A patent/IL250982B/en active IP Right Grant
- 2017-03-07 ZA ZA2017/01646A patent/ZA201701646B/en unknown
- 2017-03-14 PH PH12017500483A patent/PH12017500483A1/en unknown
- 2017-04-28 CL CL2017001071A patent/CL2017001071A1/es unknown
- 2017-05-05 CO CONC2017/0004543A patent/CO2017004543A2/es unknown
-
2019
- 2019-11-15 US US16/685,765 patent/US11988669B2/en active Active
-
2021
- 2021-06-10 CY CY20211100514T patent/CY1124223T1/el unknown
-
2024
- 2024-04-18 US US18/638,970 patent/US20240280583A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2017004543A2 (es) | Método para la cuantificación absoluta de péptidos cancerosos restringidos a hla que son procesados de forma natural | |
| MX383271B (es) | Reactivos y metodos para identificar, enriquecer y/o expandir celulas t especificas de antigeno. | |
| CL2018000307A1 (es) | Moléculas biespecíficas de unión a antígeno activadoras de células t | |
| PE20230321A1 (es) | Nuevos peptidos y nuevas combinaciones de peptidos para el uso en la inmunoterapia contra el cancer de ovario y otros tipos de cancer | |
| BR112019008560A2 (pt) | célula artificial que apresenta antígeno, método para expandir linfócitos infiltrantes de tumor, para tratar um câncer com uma população de linfócitos infiltrantes de tumor e para avaliar a potência de linfócitos infiltrantes de tumor, kit, população de linfócitos infiltrantes de tumor, e, combinação | |
| MX2017013777A (es) | Metodo para el tratamiento de cancer. | |
| AR113342A1 (es) | Anticuerpos específicos cd47 / pd-l1 | |
| EP3476934A4 (en) | METHOD FOR PRODUCING CD4 / CD8 DOUBLE POSITIVE T CELLS | |
| CR20170032A (es) | Moleculas biespecíficas de unión a antígeno activadoras de células t | |
| MX2016013963A (es) | Metodos mejorados para la elaboracion de terapias celulares adoptivas. | |
| MX2017003847A (es) | Proteinas biespecificas activables por proteasas. | |
| CL2016002004A1 (es) | Anticuerpos anti-jagged1 y métodos de uso | |
| AR102888A1 (es) | Animales no humanos que tienen un gen humanizado de agrupamiento de diferenciación 47 | |
| GB2525104A (en) | Massively parallel single cell analysis | |
| IN2014DN07531A (es) | ||
| Probst et al. | Anti-neuronal autoantibodies: current diagnostic challenges | |
| BR112017008251A2 (pt) | usos de um tecido de um porco transgênico que compreende um gene a(1,3) galactosiltransferase, cmah e ß4galnt2 interrompido e de um produto relacionado com a pele, métodos para preparação de um material de transplante para xenoenxerto, para produção de um composto de interesse e para produzir um reagente de cultura de células, e, reagente de cultura de células | |
| ES2672895T3 (es) | Generación de células T específicas de antígeno | |
| AR109451A1 (es) | Composiciones y métodos para preparar anticuerpos basados en el uso de loci mejoradores de expresión | |
| BR112016016737A2 (pt) | Peptídeos, dispositivos e métodos para detecção de anticorpos contra anaplasma | |
| CL2020001137A1 (es) | Anticuerpos anti-apoc3 y métodos de uso de estos. | |
| MX383218B (es) | Proteínas antiporter de protones/azúcar tonoplastidarias y su uso para incrementar la concentración de sacarosa en un organo vegetal acopiador de sacarosa. | |
| BR112017020513A2 (pt) | método de produção de peixe para transplante, peixe para transplante, método de produção de espécie híbrida de peixe e espécie híbrida de peixe | |
| HK1201176A1 (en) | Antigen presenting cancer vaccine | |
| BR112017001696A2 (pt) | composições de célula-tronco e métodos de produção de células-tronco para aplicações terapêuticas |